Diffusion Pharmaceuticals Inc. (DFFN) EPS Estimated At $-0.31

February 24, 2018 - By Stephen Andrade

 Diffusion Pharmaceuticals Inc. (DFFN) EPS Estimated At $ 0.31

Analysts expect Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) to report $-0.31 EPS on March, 30.They anticipate $0.06 EPS change or 24.00 % from last quarter’s $-0.25 EPS. After having $-0.37 EPS previously, Diffusion Pharmaceuticals Inc.’s analysts see -16.22 % EPS growth. The stock decreased 2.40% or $0.02 during the last trading session, reaching $0.63. About 398,927 shares traded. Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has declined 76.39% since February 24, 2017 and is downtrending. It has underperformed by 93.09% the S&P500.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The company has market cap of $31.83 million. The Company’s lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme ; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. It currently has negative earnings. The firm is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM.

More important recent Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) news were published by: Globenewswire.com which released: “Diffusion Pharmaceuticals Names William Hornung Chief Business Officer” on August 23, 2017, also Seekingalpha.com published article titled: “FDA signs off on Phase 3 protocol for Diffusion Pharma’s lead candidate TSC …”, Seekingalpha.com published: “Diffusion Pharma up 39% after Biotech Showcase presentation” on January 09, 2018. More interesting news about Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) was released by: Globenewswire.com and their article: “Diffusion Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference” with publication date: February 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.